Home›Clinical trials›The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication

A study in adults starting a GLP-1 medicine on their own prescription.

Recruiting now. Registry record last updated June 24, 2026.

Who can join
Adults 18+, have obesity, BMI 27+.
What you take
Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts
The study runs about 12 months.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Not ApplicableSponsor University of PittsburghDrug GLP-1 RAsClass OtherSites 1 USEnrollment target 40

What this study is for

Primary condition: Muscle Composition. Also studied in: Obesity, Quality of Life (QOL).

Full scientific study title: The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication.

Who can join

Age18 and upSexAnyBMI27 to 45

Adults 18+, have obesity, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Initiating GLP-1 RAs prescribed by physician or advanced practice practitioner and willing to withhold the start of the drug until baseline assessment completed
  • Non-Smoker
  • ≥18 years old
  • Obese: Body Mass Index 30-45 kg/m² or BMI ≥27 + ≥1 weight related comorbidity; either hypertension or sleep apnea confirmed by participant self-report
  • Inactive: not meeting the current US exercise guidelines over the past 6 months

Key exclusion criteria

  • A serious heart condition, such as unstable heart disease or heart failure, irregular heartbeats that are not well controlled, severe narrowing of the heart valves, or any recent inflammation of the heart or its lining
  • Cancer requiring treatment in the past 5 years
  • Hypothyroidism/hyperthyroidism
  • Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome type 2 (MEN2)
  • Gastroparesis

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Pennsylvania1 site
  • Physical Activity Research Center, University of Pittsburgh
    Pittsburgh, Pennsylvania
    Jiyeon Yoon, M.S.515-817-4601jiy239@pitt.edu

Timeline

Started enrolling: May 25, 2026. Expected completion: May 31, 2027. Last updated on ClinicalTrials.gov: June 24, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.